Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-25 @ 1:40 AM
NCT ID:
NCT03817294
Eligibility Criteria:
Inclusion Criteria:
* Male or Female, aged 40 years or above
* Diagnosis of COPD
* FEV1/FVC \<0.7 and FEV1 \< 80% predicted
* Medical Research Council (MRC) dyspnoea scale ≥3
* Participant is willing and able to give informed consent for participation in the study.
* Stable dose of current regular medication for at least 4 weeks prior to study entry.
* Participant has clinically acceptable ECG at enrolment.
* Able (in the Investigators opinion) and willing to comply with all study requirements.
* English speaking
Exclusion Criteria:
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
* Any major or uncontrolled comorbidity that would impair the participant's ability to exercise or would mean exercise was unsafe.
* Participants who have participated in another research study involving an investigational product in the past 12 weeks
* Participation in pulmonary rehabilitation in the preceding 6 months
* Participation in another research study involving exercise training in the preceding 6 months
* Acute exacerbation in the preceding 4 weeks (would become eligible 4 weeks following recovery)
* Scheduled elective surgery or other procedures requiring general anaesthesia during the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT03817294
Study Brief:
Protocol Section:
NCT03817294